An Impartial Peek At Ibrutinib

3%; p?learn more due to various underlying conditions. This probably reflects a change in our indwelling population, with larger numbers of older immunocompromised patients, due mainly to transplantation, malignancy, corticosteroids and other immunosuppressive drugs. In a recent population-based study of CAP in older adults [3], the incidence rate of CAP was almost three-fold higher among immunocompromised patients than in immunocompetent subjects. A case-control study investigating the risk of hospitalization for pneumonia in older adults in Canada found that the use of immunosuppressant medication was an important risk factor for CAP, with an OR?=?15.13 (95% CI, 4.7�C48.3; p?TRIB1 two decades ago, compared with other conditions. Although there has been a substantial decline in the number of HIV-infected patients admitted to hospital due to CAP over the last 15?years, the older age the patients in our study may explain, in part, the absence of HIV-infections. An etiological diagnosis was made in a relatively-low proportion of our patients compared with other recent studies [1]. The rate of identification of a causative agent of CAP in clinical practice is low and the etiology may remain obscure in more than half of all cases [14]. A multicenter study in the USA that assessed routine clinical practice in cases of CAP found that the cause was identified in only 25% of cases [15]. Some studies have reported even-lower diagnostic rates in the elderly, with identification of causative organisms in 5�C20% of CAP cases [16,17], perhaps indicating a reluctance to perform invasive procedures in this age-group. The distribution of microorganisms was essentially the same in immunocompromised and non-immunocompromised patients. As expected [18], S.?pneumoniae, MK-2206 which is the most frequent cause of CAP in a wide variety of immunocompromised patients, was the most-common etiological agent, independently of the immune status [11,12,19�C22]. Pseudomonas aeruginosa pneumonia occurs rarely, if at all, in non-immunocompromised patients. In a large, prospective, population-based study of 5130 patients in the German Competence Network for Community-Acquired Pneumonia (CAPNETZ study) [23], the incidence of Enterobacteriaceae and P.?aeruginosa in patients with CAP was 1.3% and 0.